Dendritic Cells Strongly Boost the Antitumor Activity of Adoptively Transferred T Cells In vivo

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Cancer Research

• Publication date

  2004-09-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1158/0008-5472.CAN-04-1621PMID 15374997PMCID PMC2241750
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T Cells

  2004influential reference
• Dendritic cells: a journey from laboratory to clinic

  2004cited by this paper
• Adoptive immunotherapy with antigen-specific T cells in myeloma: a model of tumor-specific donor lymphocyte infusion.

  2004cited by this paper
• Tumor Regression and Autoimmunity after Reversal of a Functionally Tolerant State of Self-reactive CD8+ T Cells

  2003influential reference
• Route of Immunization with Peptide-pulsed Dendritic Cells Controls the Distribution of Memory and Effector T Cells in Lymphoid Tissues and Determines the Pattern of Regional Tumor Control

  2003cited by this paper
• Adoptive-cell-transfer therapy for the treatment of patients with cancer

  2003cited by this paper
• The use of dendritic cells in cancer immunotherapy.

  2003cited by this paper
• T-cell responses of vaccinated cancer patients.

  2003cited by this paper
• Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity.

  2002cited by this paper
• Induction of CD4(+) T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.

  2002cited by this paper
• Viral interference with antigen presentation

  2002cited by this paper
• Cancer Regression and Autoimmunity in Patients After Clonal Repopulation with Antitumor Lymphocytes

  2002cited by this paper
• Rapid Induction of Specific Cytotoxic T Lymphocytes Against Melanoma-Associated Antigens by a Recombinant Vaccinia Virus Vector Expressing Multiple Immunodominant Epitopes and Costimulatory Molecules In Vivo

  2002cited by this paper
• Dendritic Cells Transduced with Protein Antigens Induce Cytotoxic Lymphocytes and Elicit Antitumor Immunity1

  2002cited by this paper
• Immunotherapy against antigenic tumors: a game with a lot of players

  2002cited by this paper
• Trafficking of CD44‐deficient murine lymphocytes under normal and inflammatory conditions

  2002cited by this paper
• Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

  2002cited by this paper
• Preferential Localization of Effector Memory Cells in Nonlymphoid Tissue

  2001cited by this paper
• Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction

  2001cited by this paper
• Induction of systemic CTL responses in melanoma patients by dendritic cell vaccination: Cessation of CTL responses is associated with disease progression

  2001cited by this paper
• Adoptive Transfer of Cloned Melanoma-Reactive T Lymphocytes for the Treatment of Patients with Metastatic Melanoma

  2001cited by this paper
• Dendritic cells: specialized and regulated antigen processing machines.

  2001cited by this paper
• Gene therapy: promises and problems.

  2001cited by this paper
• Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells1

  2000cited by this paper
• Traffic of L‐selectin‐negative T cells to sites of inflammation

  2000cited by this paper
• Reversal of CD8+ T Cell Ignorance and Induction of Anti-Tumor Immunity by Peptide-Pulsed APC1

  2000cited by this paper
• T Cell Activity After Dendritic Cell Vaccination Is Dependent on Both the Type of Antigen and the Mode of Delivery1

  2000cited by this paper
• Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes.

  2000cited by this paper
• T-cell adoptive immunotherapy of metastatic renal cell carcinoma.

  1999cited by this paper
• Antigen capture, processing, and presentation by dendritic cells: recent cell biological studies.

  1999cited by this paper
• Induction and visualization of mucosal memory CD8 T cells following systemic virus infection.

  1999cited by this paper
• Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines.

  1999cited by this paper
• Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

  1999cited by this paper
• Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial.

  1999cited by this paper
• Mature T lymphocyte apoptosis--immune regulation in a dynamic and unpredictable antigenic environment.

  1999cited by this paper
• Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.

  1998cited by this paper
• gp100/pmel 17 Is a Murine Tumor Rejection Antigen: Induction of “Self”-reactive, Tumoricidal T Cells Using High-affinity, Altered Peptide Ligand

  1998cited by this paper
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells

  1998cited by this paper
• Dendritic cells and the control of immunity

  1998cited by this paper
• Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors.

  1997cited by this paper
• Requirement for CD44 in activated T cell extravasation into an inflammatory site.

  1997cited by this paper
• Treatment of subcutaneous tumor with adoptively transferred T cells.

  1997cited by this paper
• Dendritic Cells Retrovirally Transduced with a Model Antigen Gene Are Therapeutically Effective against Established Pulmonary Metastases

  1997cited by this paper
• Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

  1996cited by this paper
• Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens

  1996cited by this paper
• Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.

  1994cited by this paper
• Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action

  1990cited by this paper
• Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction.

  1990cited by this paper
• Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma.

  1989cited by this paper
• A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

  1986cited by this paper
• Cytotoxicity of human rosette‐forming blood lymphocytes on cultivated human tumor cells

  1974cited by this paper
• Studies on the mechanism of action of dantrolene sodium

  1972cited by this paper

• Engineered immune cell therapies for solid tumors: pharmacological advances, clinical outcomes, and future directions

  2025cites this paper
• Current status and perspectives of clinical trials for tumor-infiltrating lymphocyte therapy

  2024cites this paper
• An Overview of the Immune Modulatory Properties of Long Non-Coding RNAs and Their Potential Use as Therapeutic Targets in Cancer

  2023cites this paper
• Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade

  2023cites this paper
• Adoptive Transfer of Anti-Nucleolin T Cells Combined with PD-L1 Inhibition against Triple-Negative Breast Cancer

  2022cites this paper
• Cytotoxic T Cells Activated by Self-differentiated Monocyte-derived Dendritic Cells Against Multiple Myeloma Cells

  2022cites this paper
• CXCL1 promotes colon cancer progression through activation of NF-κB/P300 signaling pathway

  2022cites this paper
• Vaccines as Priming Tools for T Cell Therapy for Epithelial Cancers

  2021cites this paper
• AIM2 regulates anti-tumor immunity and is a viable therapeutic target for melanoma

  2021influential citation
• Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma

  2021cites this paper
• Activity-regulated cytoskeleton-associated protein/activity-regulated gene 3.1 (Arc/Arg3.1) enhances dendritic cell vaccination in experimental melanoma

  2021cites this paper
• Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction

  2020cites this paper
• Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal

  2020cites this paper
• The Roles of Alternative Splicing in Tumor-immune Cell Interactions

  2020cites this paper
• Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s.

  2020cites this paper
• Study the Effect of Star Anise Extract and the Pulp of Kiwifruit on Mice Infected with Cancer

  2020cites this paper
• IL-9 and IL-9-producing cells in tumor immunity

  2020cites this paper
• Correction to: Current Advances in Osteosarcoma.

  2020cites this paper
• Impact of interleukin-7 on the differentiation and anti-tumor capabilities of CD8+ T cells

  2020cites this paper
• Innovative strategies to advance CAR T cell therapy for solid tumors.

  2020cites this paper
• Leveraging Endogenous Dendritic Cells to Enhance the Therapeutic Efficacy of Adoptive T-Cell Therapy and Checkpoint Blockade

  2020cites this paper
• Effect of star anise extract and pulp of kiwifruit on cancer in mice

  2019cites this paper
• Inosine is an alternative carbon supply that supports effector T cell proliferation and antitumor function under glucose restriction

  2019cites this paper
• Tumor-Resident Dendritic Cells and Macrophages Modulate the Accumulation of TCR-Engineered T Cells in Melanoma

  2018cites this paper
• Antitumor activity of CAR-T cells targeting the intracellular oncoprotein WT1 can be enhanced by vaccination.

  2018cites this paper
• 19F-MRI to Monitor Therapeutic Cell Migration and Distribution

  2018cites this paper
• A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

  2018cites this paper
• A phase I clinical trial of RNF43 peptide-related immune cell therapy combined with low-dose cyclophosphamide in patients with advanced solid tumors

  2018cites this paper
• Dendritic Cell-Based Immunotherapy for Solid Tumors12

  2018cites this paper
• Tuning cancer fate: the unremitting role of host immunity

  2017cites this paper
• Cell Based Therapy: Modified Cancer Cells

  2017cites this paper
• Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination

  2016cites this paper
• Novel Treatments in Development for Melanoma.

  2016cites this paper
• A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.

  2015cites this paper
• Acute inflammation induces immunomodulatory effects on myeloid cells associated with anti-tumor responses in a tumor mouse model

  2015cites this paper
• Splenic Dendritic Cells Involved in Cross-Tolerance of Tumor Antigens Can Play a Stimulatory Role in Adoptive T-Cell Therapy

  2015cites this paper
• Vaccines, Adjuvants, and Dendritic Cell Activators--Current Status and Future Challenges.

  2015cites this paper
• Rationale for a Multimodality Strategy to Enhance the Efficacy of Dendritic Cell-Based Cancer Immunotherapy

  2015cites this paper
• multi-trimeric fusion of CD 40 L and gp 100 tumor antigen activates endritic cells and enhances survival in a B 16-F 10 melanoma DNA accine model

  2015cites this paper
• Identification of the Genomic Insertion Site of Pmel-1 TCR α and β Transgenes by Next-Generation Sequencing

  2014cites this paper
• Cancer and the Cellular Immune Response

  2014cites this paper
• Tumor-specific IL-9–producing CD8+ Tc9 cells are superior effector than type-I cytotoxic Tc1 cells for adoptive immunotherapy of cancers

  2014cites this paper
• Superior anti-tumor protection and therapeutic efficacy of vaccination with dendritic cell/tumor cell fusion hybrids for murine Lewis lung carcinoma

  2014cites this paper
• Prolonged repeated vaccine immuno-chemotherapy induces long-term clinical responses and survival for advanced metastatic melanoma

  2014cites this paper
• Adoptive Transfer of MART-1 T-Cell Receptor Transgenic Lymphocytes and Dendritic Cell Vaccination in Patients with Metastatic Melanoma

  2014influential citation
• Genetically modified T-cell therapy for osteosarcoma.

  2014cites this paper
• Adoptive T-cell Transfer and Chemotherapy in the First-line Treatment of Metastatic and/or Locally Recurrent Nasopharyngeal Carcinoma

  2013cites this paper
• Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer

  2013cites this paper
• obviates the requirement for in vivo vaccination T cells in vitro + Programming tumor-reactive effector memory CD8

  2013cites this paper
• Monitoring immune responses in dendritic cell based vaccination with a focus on in vivo imaging

  2013cites this paper
• Cellular Immunotherapy Using Dendritic Cells in Multiple Myeloma: New Concept to Enhance Efficacy

  2013cites this paper
• Dendritic Cell-Based Cancer Immunotherapy: Achievements and Novel Concepts

  2013cites this paper
• Improved Active Therapy of Tumors Receptor Expressing T Cells Provides Combination of Vaccination and Chimeric

  2013cites this paper
• Adoptive Cell Therapy for the Treatment of Metastatic Melanoma

  2012cites this paper
• Agonistic Antibody to CD40 Boosts the Antitumor Activity of Adoptively Transferred T Cells In Vivo

  2012cites this paper
• BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice

  2012cites this paper
• The activation, by antigen, of naïve TCR transgenic CD4 T cells cultured at physiological, rather than artificially high, frequencies more accurately reflects the in vivo activation of normal numbers of naïve CD4(+) T cells.

  2012cites this paper
• THE CYTOPLASMIC TAIL OF MHC CLASS I MOLECULES PLAYS A CRITICAL ROLE IN DENDRITIC CELL-INDUCED T CELL IMMUNITY

  2011influential citation
• Antitumor Activity Mediated by CpG: The Route of Administration is Critical

  2011cites this paper
• Therapeutic cancer vaccines: are we there yet?

  2011cites this paper
• Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice

  2011cites this paper
• Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

  2011cites this paper
• Therapeutic vaccines in renal cell carcinoma.

  2011cites this paper
• Natural Splice Variant of MHC Class I Cytoplasmic Tail Enhances Dendritic Cell-Induced CD8+ T-Cell Responses and Boosts Anti-Tumor Immunity

  2011cites this paper
• Current status and future applications of cellular therapies for cancer.

  2011cites this paper
• Qualitative und quantitative Analyse und Vergleich von Tumorantigenen und HLA Klasse I-Liganden in Primärtumoren und Metastasen des Nierenzellkarzinoms

  2011cites this paper
• CD34+ Cord Blood DC-induced Antitumor Lymphoid Cells Have Efficacy in a Murine Xenograft Model of Human ALL

  2011cites this paper
• Cancer Therapy : Preclinical Determinants of Successful CD 8 þ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

  2011cites this paper
• Systemic therapy for advanced hepatocellular carcinoma: past, present, and future.

  2010cites this paper
• Clinical Cancer esearch cer Therapy : Preclinical nsduction of Tumor-Specific T Cells with CXCR 2 mokine Receptor Improves Migration to R or and Antitumor Immune Responses

  2010cites this paper
• Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters

  2010cites this paper
• Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination

  2010influential citation
• Characterization and optimization of antigen-specific T cell responses during ex vivo expansion of melanoma tumor-infiltrating lymphocytes

  2010cites this paper
• Transduction of Tumor-Specific T Cells with CXCR2 Chemokine Receptor Improves Migration to Tumor and Antitumor Immune Responses

  2010cites this paper
• Significant anti‐tumour activity of adoptively transferred T cells elicited by intratumoral dendritic cell vaccine injection through enhancing the ratio of CD8+ T cell/regulatory T cells in tumour

  2010cites this paper
• Changes in Dendritic Cell Phenotype After a New High-dose Weekly Schedule of Interleukin-2 Therapy for Kidney Cancer and Melanoma

  2010cites this paper
• nsduction of Tumor-Specific T Cells with CXCR2 mokine Receptor Improves Migration to

  2010cites this paper
• Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.

  2010cites this paper
• Immunostimulatory cancer chemotherapy using local ingenol-3-angelate and synergy with immunotherapies.

  2009cites this paper
• The effect of manipulating apoptotic cell uptake on their immunogenicity

  2009cites this paper
• T helper 17 cells promote cytotoxic T cell activation in tumor immunity.

  2009cites this paper
• Radiotherapy Combined With Intratumoral Dendritic Cell Vaccination Enhances the Therapeutic Efficacy of Adoptive T-cell Transfer

  2009cites this paper
• Recovery from Cyclophosphamide-Induced Lymphopenia Results in Expansion of Immature Dendritic Cells Which Can Mediate Enhanced Prime-Boost Vaccination Antitumor Responses In Vivo When Stimulated with the TLR3 Agonist Poly(I:C)1

  2009cites this paper
• Programming tumor-reactive effector memory CD8+ T cells in vitro obviates the requirement for in vivo vaccination.

  2009cites this paper
• Clinical and Immunologic Effects of Intranodal Autologous Tumor Lysate-Dendritic Cell Vaccine with Aldesleukin (Interleukin 2) and IFN-α2a Therapy in Metastatic Renal Cell Carcinoma Patients

  2009cites this paper
• Clinical development of combination strategies in immunotherapy: are we ready for more than one investigational product in an early clinical trial?

  2009cites this paper
• Quantitative PET reporter gene imaging of CD8+ T cells specific for a melanoma-expressed self-antigen

  2008cites this paper
• Dendritic cells in cancer immunotherapy.

  2008cites this paper
• Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells.

  2008cites this paper
• Memory T cells in cancer immunotherapy: which CD8 T-cell population provides the best protection against tumours?

  2008cites this paper
• Interleukin-21 augments the efficacy of T-cell therapy by eliciting concurrent cellular and humoral responses.

  2008cites this paper
• The anticancer immune response: indispensable for therapeutic success?

  2008cites this paper
• Cell-Based Vaccines for Renal Cell Carcinoma

  2008cites this paper
• Dendritic cell vaccines in melanoma: from promise to proof?

  2008cites this paper
• Assessing vaccine potency using TCRmimic antibodies.

  2008cites this paper
• Adjuvant effect of anti-4-1BB mAb administration in adoptive T cell therapy of cancer

  2007cites this paper
• Developing a Rational Tumor Vaccine Therapy for Renal Cell Carcinoma: Immune Yin and Yang

  2007cites this paper
• To ablate or not to ablate? HSCs in the T cell driver's seat.

  2007cites this paper
• IRX-2, a Novel In Vivo Immunotherapeutic, Induces Maturation and Activation of Human Dendritic Cells In Vitro

  2007cites this paper
• Toll-like Receptors inTumor Immunotherapy

  2007cites this paper